Rapid Field Appropriate Diagnostics for Select Biodefense and Emerging Pathogens

Information

  • Research Project
  • 9068657
  • ApplicationId
    9068657
  • Core Project Number
    R33AI100182
  • Full Project Number
    5R33AI100182-05
  • Serial Number
    100182
  • FOA Number
    RFA-AI-11-024
  • Sub Project Id
  • Project Start Date
    6/1/2012 - 14 years ago
  • Project End Date
    5/31/2017 - 9 years ago
  • Program Officer Name
    REPIK, PATRICIA M.
  • Budget Start Date
    6/1/2016 - 10 years ago
  • Budget End Date
    5/31/2017 - 9 years ago
  • Fiscal Year
    2016
  • Support Year
    05
  • Suffix
  • Award Notice Date
    5/26/2016 - 10 years ago
Organizations

Rapid Field Appropriate Diagnostics for Select Biodefense and Emerging Pathogens

Expensive equipment, highly-trained personnel, and the need for a clinical laboratory setting precludes routine nucleic acid testing (NAT) for infectious disease in most of the developing world and even in many resource-limited parts of the United States, leading to wide disparities in health care worldwide. A fast, sensitive, low cost but facile NAT method for robust detection of specific agents at point of care (POC) would help bring molecular diagnostics to everyone. The goal of this application is to demonstrate feasibility of a complete field-appropriate NAT diagnostics system for detection of viral hemorrhagic fever (VHF) RNA for low resource settings. The innovative technology that is the basis of this application is a new thermostable polymerase with innate reverse transcriptase (RT) activity called PyroScript. PyroScript can perform a promising NAT alternative to the polymerase chain reaction (PCR) called loop mediated isothermal amplification (LAMP). Since LAMP is isothermal it does not require specialized instrumentation plus it is much faster than PCR. LAMP is also resistant to inhibitors in crude sample preparations. The PyroScript polymerase is the only known thermostable enzyme combining both strand displacement activity for LAMP-based amplification and RT activity to amplify directly from RNA. The technical advantages of this enzyme are: 1) A single stable enzyme unlike methods requiring two or more labile enzymes to detect RNA. 2) Thermophilic PyroScript can be denatured at 95¿C. 3) Rapid isothermal amplification from RNA with PyroScript in under 30 minutes. The goal of the proposed research is to further improve PyroScript NAT reagent formulations to provide field-capable stability performance. Another goal is to develop a nucleic acid sample preparation method with ease of use suitable for point of care implementation. These innovations will be combined into locally relevant diagnostic panels that can be performed to test for pathogens endemic to a specific region. By combining Lucigen s capacity in amplification and detection with the expertise in VHF research and fundamental capability provided by the Galveston National Laboratory a NAT system will be developed for detection of viral RNA that can be implemented almost anywhere, worldwide.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R33
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
    402337
  • Indirect Cost Amount
    43250
  • Total Cost
    445587
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:445587\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    NSS
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    LUCIGEN CORPORATION
  • Organization Department
  • Organization DUNS
    019710669
  • Organization City
    MIDDLETON
  • Organization State
    WI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    535621614
  • Organization District
    UNITED STATES